Navigation Links
Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat

Enterprise appoints founding president of Canadian Institutes of Health

Research to head global effort to coordinate HIV vaccine development

CAPE TOWN, South Africa, Oct. 11 /PRNewswire-USNewswire/ -- At the Keystone Symposium in Cape Town today, the Global HIV Vaccine Enterprise announced the appointment of its first executive director and the opening of a new secretariat in New York City. Dr. Alan Bernstein, founding president of the Canadian Institutes of Health Research, will lead the international alliance of researchers, funders and advocates dedicated to speeding the search for an HIV vaccine.

Dr. Bernstein's appointment comes after the recent announcements by Merck, the HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID) regarding the discontinuation of immunizations in the STEP HIV vaccine trial.

"The scientific challenges of developing an HIV vaccine are enormous, but the Enterprise's collaborative vision is a source of tremendous hope," said Dr. Bernstein. "The challenge now is to build on this momentum and implement a coherent, integrated and global scientific strategy that will hasten development of an effective and safe vaccine. The world expects nothing less of all those engaged in this endeavor."

The Global HIV Vaccine Enterprise is charged by its founders with setting scientific priorities, mobilizing resources, and improving collaboration in the HIV vaccine field. Originally proposed by 24 leading HIV vaccine researchers in 2003, the Enterprise has to date mobilized more than US$750 million in support of its scientific strategic plan. The Enterprise's plan focuses on six key research areas: vaccine discovery, laboratory standardization, product development and manufacturing, clinical trials capacity, regulatory issues and intellectual property.

The Enterprise today also announced the opening of its first independent secretariat in New York and new funding commitments to support the coordinating role of the secretariat. The US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has awarded up to US$7 million over the next seven years, and the Bill & Melinda Gates Foundation has committed $20 million over the next four years to support the secretariat's activities.

"The enormous scientific obstacles in identifying an effective HIV vaccine combined with the urgent need for improved HIV prevention support the need for increased coordination and collaboration globally to accelerate progress," said Anthony S. Fauci, M.D., Director of NIAID. "Dr. Bernstein has a proven track record building a world-class scientific organization that brings together researchers, funders, advocates and industry. The Enterprise, under Dr. Bernstein's leadership, can bring new energy to the HIV vaccine field and help us work together in a coordinated manner to tackle these major obstacles as quickly as possible."

Dr. Bernstein was previously the founding president of the Canadian Institutes of Health Research. Over the past seven years, he has built CIHR into one of the world's leading research agencies, supporting more than 11,000 health researchers with an annual budget of US$1 billion.

"Alan Bernstein's appointment as executive director brings increased momentum to the Enterprise's essential efforts to help accelerate the search for an HIV vaccine," said Dr. Seth Berkley, President and CEO of the International AIDS Vaccine Initiative. "This is a wonderful opportunity for those of us working in the field to derive an added level of synergy by working together across all stages of HIV vaccine development."

"The Enterprise has an important role to play in ensuring that HIV vaccine development efforts match the magnitude of the pandemic. The 2005 Enterprise scientific plan charts a broad path forward - we must explore multiple approaches and aggressively pursue novel scientific leads, working together in new ways," said Dr. Jos Esparza, senior advisor on HIV vaccines for the Bill & Melinda Gates Foundation. "The Gates Foundation is committed to supporting the Enterprise secretariat, and to helping advance priorities in the Enterprise scientific plan through our support of the Collaboration for AIDS Vaccine Discovery."

Dr. Bernstein received his Ph.D. in Medical Biophysics at the University of Toronto. Following postdoctoral work in London where he first began working on retroviruses, he returned to Canada to join the faculty of the Ontario Cancer Institute. He later served as head of the Division of Molecular and Developmental Biology at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, and then its director of research.

An internationally renowned researcher, he has made extensive contributions to the study of embryonic development, hematopoiesis and cancer. Dr. Bernstein has received a number of national and international awards for his research, and has served on a large number of international scientific bodies, including the scientific board of the Grand Challenges in Global Health initiative.

"HIV affects more than 40 million people worldwide, and nearly 5 million people are newly infected every year," said Dr. Helene Gayle, President and CEO of CARE and chair of the Enterprise coordinating committee. "An HIV vaccine, once developed, has the potential to save millions of lives and stop this pandemic. The Enterprise can speed the day when AIDS will no longer threaten us or our children."

About the Global HIV Vaccine Enterprise:

The Global HIV Vaccine Enterprise is an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine by implementing a shared scientific plan, mobilizing significant new funding for vaccine research, and promoting more efficient, faster ways for researchers to share successes and failures and avoid duplicating their efforts. The Enterprise brings together researchers, funders, and advocates from academia, government agencies, private industry, and non-governmental organizations in developed and developing countries. The Enterprise also engages the broader international community to support HIV vaccine research and make it an integral part of the global response to HIV/AIDS.

SOURCE The Global HIV Vaccine Enterprise
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
7. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
8. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
9. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
(Date:11/25/2015)... -- The American Academy of Pediatrics (AAP), American Congress ... of Dimes cheered today,s signature into law of ... 2015 (S.799), which takes much-needed strides to ... drugs, such as opioids, and to improve their ... have worked together leading advocacy efforts for its ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... ... 25, 2015 , ... As part of a global movement ... volunteers together who want to combine talents and resources to help create sustainable ... process. The non-profit launched its first major fundraiser on November 6, 2015 at ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
Breaking Medicine News(10 mins):